Smart Market Insights
Pramodini Medicare IPO Details: Key Dates, Price Band & Investment Overview
By Wealthova | Last Updated: August 7, 2026
Pramodini Medicare Limited is gearing up to make its primary market debut with an upcoming ₹69.04 Crore SME IPO. Operating as a fast-growing diagnostic service provider, the company offers technology-enabled radiology, clinical laboratory, and nuclear medicine services across multiple states in India. The subscription window for this book-built issue opens on August 12 and closes on August 14, 2026. The price band is set between ₹110 to ₹118 per equity share, comprising a ₹63.14 Crore fresh issue and a ₹5.90 Crore Offer for Sale (OFS). The company plans to utilize the fresh capital to fund critical capital expenditure for purchasing new medical equipment for its existing and proposed diagnostic centers. Set to list exclusively on the NSE SME platform, market participants are closely watching this healthcare stock. Below, we break down the financial health, risk factors, and our honest Smart Market Insights to help you decide if you should subscribe to this issue!
Pramodini Medicare IPO Details
Quick IPO Factsheet
August 12, 2026
August 14, 2026
₹110 to ₹118
1,200 Shares
₹69.04 Cr
₹63.14 Cr
35% Allocation
₹10 Base
NSE SME IPO
Pramodini Medicare IPO Timeline
Deep-Dive Corporate Profile: What the Company Does?
Pramodini Medicare Limited is a specialized and rapidly expanding diagnostic healthcare provider that leverages technology-enabled systems to deliver testing, screening, and disease monitoring services. Based heavily in Andhra Pradesh, the company operates a robust network of diagnostic centers that cater to both private patients and government-backed healthcare initiatives.
The company's core healthcare operations and service portfolio include:
- Comprehensive Radiology Services: The company is heavily focused on advanced imaging, offering Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X-ray, Ultrasound with colour doppler, Mammography, Dexa Scan, and Intervention Radiology.
- Advanced Clinical Laboratory Testing: Their diagnostic labs manage a wide spectrum of tests, primarily focusing on Haematology and Micro-Biology. These labs execute both routine check-ups and highly specialized tests crucial for the prediction, early detection, and ongoing monitoring of complex health conditions.
- 24x7 Teleradiology Network: To ensure round-the-clock service delivery and faster report turnarounds, Pramodini Medicare operates a dedicated teleradiology hub from its registered office in Vijayawada, functioning 24x7 throughout the year.
- Public Private Partnerships (PPP): A major differentiator for the company is its strong B2G (Business-to-Government) revenue stream. A significant portion of its operational income is secured through strategic Memorandums of Understanding (MOUs) with government authorities to run diagnostic facilities within government hospitals under the PPP model.
Why is the Company Raising Funds? (Objects of the Issue)
The Pramodini Medicare IPO aims to raise ₹69.04 Crore, consisting of a ₹63.14 Crore Fresh Issue and a small ₹5.90 Crore Offer for Sale (OFS).
The company proposes to utilize the net proceeds from the fresh issue segment for the following strategic objectives:
- Medical Equipment & Capital Expenditure: The primary focus of the fresh capital is funding the purchase of advanced medical equipment. This machinery will be deployed to upgrade their existing diagnostic centers and fully equip new, proposed diagnostic facilities to expand their service footprint.
- Unidentified Inorganic Acquisitions: A portion of the proceeds is earmarked to fund strategic, unidentified inorganic acquisitions, allowing the company to rapidly scale its network by acquiring existing smaller diagnostic chains or localized centers.
- General Corporate Purposes: The remaining balance will be retained to cover day-to-day operational liquidity, administrative requirements, and other general corporate initiatives.
Company Financials
| 📅 Period Ended | 📈 Total Income | 📉 Expense & Tax | 💰 PAT | 🏦 Assets |
|---|---|---|---|---|
| FY 2024 | ₹35.79 | ₹28.86 | ₹6.93 | ₹48.78 |
| FY 2025 | ₹38.55 | ₹27.52 | ₹11.03 | ₹56.45 |
| FY 2026 | ₹63.38 | ₹46.00 | ₹17.38 | ₹93.62 |
Pramodini Medicare IPO Key Performance Indicators (KPIs)
| Financial KPI (FY2026)* | Value |
|---|---|
| Return on Equity (ROE) | 60.91% |
| Return on Capital Employed (ROCE) | 61.94% |
| EBITDA Margin | 42.61% |
| PAT Margin | 27.53% |
| Debt to Equity Ratio | 0.00 |
| Earnings Per Share (EPS) | ₹11.53 (Basic) |
| Price/Earning (P/E) Ratio | ~10.23x (at upper price band) |
Smart Market Insights
Pramodini Medicare Limited presents a highly compelling opportunity in the rapidly expanding diagnostic healthcare space. The financials are exceptionally robust, boasting a massive 60.91% ROE, 61.94% ROCE, and a flawless zero-debt balance sheet prior to the IPO. The company has demonstrated excellent operational efficiency, effectively doubling its revenue from FY24 to FY26 while maintaining a lucrative PAT margin of 27.53%. Furthermore, the allocation of over 71% of the fresh issue proceeds directly toward medical equipment ensures that capital is being deployed for tangible revenue generation. At the upper price band of ₹118, the stock is valued at a P/E of just ~10.23x, which is highly attractive for a high-growth healthcare technology player and leaves a comfortable margin of safety for investors.
- The Bull Case: Impeccable financial health characterized by zero borrowings and phenomenal return ratios (ROE > 60%). The unique B2G (Business-to-Government) Public-Private Partnership model provides sustained revenue visibility and a built-in patient base. The valuation (10.23x P/E) is arguably underpriced for the sector.
- The Bear Case: High geographic concentration, with operations predominantly rooted in Andhra Pradesh, limiting pan-India brand visibility. Additionally, heavy reliance on government contracts means receivables and cash flows could be subject to bureaucratic delays. The diagnostic sector remains heavily capital-intensive and requires continuous, expensive technological upgrades.
Disclaimer: The information provided above is for educational and informational purposes only and does not constitute financial advice. SME listings are inherently highly volatile, carry lower liquidity, and involve significant risk. Wealthova is not a SEBI-registered investment advisor. Always consult with a certified financial planner and conduct your own due diligence before locking up capital in any public issue.
Pramodini Medicare IPO Key Contacts & Advisors
| Role / Entity | Contact & Details |
|---|---|
| 📋 IPO Registrar |
Purva Sharegistry (India) Pvt. Ltd.
Phone: +91 22 4134 3255
Email: newissue@purvashare.com
Website: purvashare.com
|
| 🏢 Company Contact |
Pramodini Medicare Limited
D. No: 29-4-54K, CSI Complex, Prakasam Road, Suryaraopet, Vijayawada, Andhra Pradesh - 520002, India
Phone: +91 99857 82727
Email: investors@pramodinidiagnostics.com
Website: pramodinidiagnostics.com
|
| 💼 Merchant Bankers |
Book Running Lead Manager:
|
Frequently Asked Questions (FAQs)
What are the opening and closing dates for the Pramodini Medicare IPO?
What is the minimum lot size and investment required for retail investors?
How can I check the allotment status for Pramodini Medicare IPO?
- Wealthova (Recommended): Check directly on the Wealthova IPO Allotment Status Hub using your PAN Card number or Application Number for instant results.
- Official Registrar Portal: Visit the official portal of Purva Sharegistry (India) Pvt. Ltd.
- Stock Exchange Web Portals: Verify directly on the official NSE SME allotment verification page.